evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

290 questions · 295 findings · 24 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 73 · 24.7%GRADE not reported 23 · 7.8%Very low 55 · 18.6%Low 96 · 32.5%Moderate 37 · 12.5%High 11 · 3.7%

Glutamine vs placebo

Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies

It is very uncertain whether summary of findings: Glutamine changes incidence of hepatic veno‐occlusive disease ( compared with placebo (very low certainty).

1 finding from 1 review

Glutamine vs placebo

All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with haematological malignancies

It is very uncertain whether summary of findings: Glutamine changes all‐cause mortality at 100 days post‐transplant ( compared with placebo (very low certainty).

1 finding from 1 review

Glutamine vs placebo

Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies

It is very uncertain whether summary of findings: Glutamine changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid vs placebo or no treatment

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).

1 finding from 1 review

Ursodeoxycholic acid vs placebo or no treatment

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Ursodeoxycholic acid changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid vs placebo or no treatment

Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Ursodeoxycholic acid changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Ruxolitinib vs placebo

Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF

Ruxolitinib may leads to higher safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with placebo (low certainty).

1 finding from 1 review

Ruxolitinib vs placebo

Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form · Patients with treating MF

Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).

1 finding from 1 review

Plerixafor vs placebo

Mortality (12 months) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma

Plerixafor showed no clear difference in mortality (12 months) compared with placebo (moderate certainty).

1 finding from 1 review